Summit Investment Advisors Inc. Trims Stock Position in Eli Lilly and Company $LLY

Summit Investment Advisors Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 20,198 shares of the company’s stock after selling 186 shares during the quarter. Eli Lilly and Company accounts for about 13.7% of Summit Investment Advisors Inc.’s portfolio, making the stock its 24th largest holding. Summit Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $16,682,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of LLY. Bensler LLC grew its position in Eli Lilly and Company by 5.5% during the second quarter. Bensler LLC now owns 17,927 shares of the company’s stock valued at $13,974,000 after buying an additional 934 shares during the period. AE Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 8.9% during the second quarter. AE Wealth Management LLC now owns 68,235 shares of the company’s stock worth $53,193,000 after purchasing an additional 5,592 shares in the last quarter. Stokes Family Office LLC lifted its stake in Eli Lilly and Company by 2.3% in the 2nd quarter. Stokes Family Office LLC now owns 4,208 shares of the company’s stock valued at $3,280,000 after buying an additional 96 shares in the last quarter. Paradigm Asset Management Co. LLC raised its position in shares of Eli Lilly and Company by 200.0% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 1,050 shares of the company’s stock valued at $819,000 after buying an additional 700 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in Eli Lilly and Company in the second quarter worth approximately $1,180,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday. UBS Group upped their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Friday. Guggenheim reiterated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $960.88.

Eli Lilly and Company Price Performance

LLY stock opened at $923.35 on Friday. The stock has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $955.46. The business has a 50 day moving average price of $799.97 and a 200 day moving average price of $775.76.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 4,314 shares of company stock worth $2,766,929 in the last 90 days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.